Moderna expands beyond vaccines as Recursion leans into AI drug discovery, sharpening a biopharma bet for 2026

Moderna and Recursion are drawing fresh attention from investors looking for the next leg of growth in biotechnology, but the companies are pursuing that goal through markedly different models. Moderna is presented as moving beyond its vaccine origins, while Recursion is positioned around AI-driven discovery efforts that aim to shorten the time between a hypothesis and a candidate drug. The contrast matters because it changes what can go right, and what can go wrong, in each business.

The comparison emphasizes Moderna’s broader platform ambitions. Instead of relying solely on vaccines and immune-focused approaches, the company is being characterized as expanding into new areas of drug development. For Moderna, the core question for 2026 becomes whether its biology-driven “platform” can translate into a steady flow of programs beyond the specific demand cycles of infectious disease.

For Recursion, the framing is different: the company is described as betting on AI-enabled drug discovery. In this model, Recursion’s value proposition is less about manufacturing or established clinical franchises and more about whether its data-and-model approach can identify promising targets and candidates quickly, then convert those leads into credible clinical outcomes.

In practical terms, investors may treat the two risk profiles as opposites. Moderna’s challenge is often described as execution across multiple development and commercial fronts, where progress depends on clinical results and on scaling programs that can sustain revenue growth over time. Recursion’s challenge is to prove that AI and large-scale experimentation can consistently generate drug candidates that succeed in human trials, despite the inherent uncertainty in translating “announcement” from data to biology.

The broader backdrop is also part of the story. Genetic Engineering and Biotechnology News pointed to growing optimism in 2026, citing improvements in biopharma sentiment after a rougher stretch for parts of the industry. In particular, the publication noted that analysts at William Blair pointed to the SPDR S&P Biotech exchange-traded fund (XBI) rebounding sharply from earlier lows, which they tied to expectations of more deal activity and stronger data and launches.

That sector optimism is tempered by a reminder that biopharma performance depends on what happens in clinics and on how pricing and regulation evolve. The GEN report said analysts still saw unanswered questions around drug pricing and FDA-related frameworks, even as they argued that clinical strength and commercial launches could keep sector momentum. For both Moderna and Recursion, market appetite in 2026 may hinge on whether they can deliver results that investors can underwrite, not just promising early activity.

What is not settled in the comparison, based on the information provided in the post, is the level of operational specificity for either company. The write-up does not supply detailed financial figures, pipeline updates, trial milestones, partnership terms, or forward guidance in the material available here. As a result, readers are left with a high-level differentiation between “expanding beyond vaccines” and “AI-driven discovery,” rather than a documented scorecard.

Investors and analysts will likely watch for a similar set of catalysts regardless of strategy: evidence of clinical progress that investors can map to timelines, and concrete progress translating discovery work into registrational or near-registrational development. For Moderna, that means milestones across its expansion efforts beyond legacy vaccine work. For Recursion, it means indicates that AI-enabled discovery can repeatedly produce candidates that withstand clinical scrutiny, not just data-driven novelty.